🇯🇵 Japan Country × Condition
ovarian cancer Clinical Trials in Japan
Active clinical trials for ovarian cancer with research sites in Japan. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 2 // Recruiting: 2 Phases: Phase 3, Phase 1, Phase 2 // Updated: Daily
Total Trials
2
Recruiting Now
2
Country
🇯🇵 Japan
Active Trials in Japan (2)
NCT07225270 Phase 3
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Enrollment
544 pts
Country
🇯🇵 Japan
Genmab
View Trial → NCT06943521 Phase 1, Phase 2
Recruiting
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Enrollment
27 pts
Country
🇯🇵 Japan
Tanabe Pharma America, Inc.
View Trial → Frequently Asked Questions
How many ovarian cancer clinical trials are active in Japan?
There are currently 2 active clinical trials for ovarian cancer with sites in Japan, of which 2 are actively recruiting patients.
How can I join a ovarian cancer clinical trial in Japan?
To join a ovarian cancer clinical trial in Japan, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Japan directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are ovarian cancer trials in Japan?
Active ovarian cancer trials in Japan span Phase 3, Phase 1, Phase 2. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology